TC
KROS icon

Telemus Capital’s Keros Therapeutics KROS Stock Holding History

Telemus Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,000
Closed -$775K – 408
2020
Q3 		$775K Buy
15,000
+5,000
+50% +$198K 0.06% 232
2020
Q2 		$328K Buy
+10,000
New +$308K 0.03% 329

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Telemus Capital's KROS Position: Q4 2020 in Review

Telemus Capital sold out of Keros Therapeutics (KROS) in Q4 2020, closing a stake of 15,000 shares — an estimated $775K sold.

Telemus Capital first reported a position in KROS in Q2 2020 and held it in 2 quarters. The position peaked at $775K in Q3 2020. 81 funds tracked by Wall St. Rank hold KROS as of Q4 2020.

  • Telemus Capital reported no remaining Keros Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Telemus Capital sold 15,000 Keros Therapeutics shares in Q4 2020, an estimated $775K.
  • Telemus Capital first reported a position in Keros Therapeutics in Q2 2020 and held it in 2 quarters.
  • Telemus Capital's Keros Therapeutics position peaked at $775K in Q3 2020.
  • 81 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.